← All drugs Report issue

pwt-33579

Small moleculeexperimental

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

1

Phase 2

0

Phase 3

0

Phase 4

0

Earliest trial started Jun 1, 2011 (NCT01407380)

Timeline

2010s

Jan 1, 2011
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Neoplasms · Phase 1

Mechanism of action

PI3-kinase p110-alpha subunitINHIBITOR
PIK3CA inhibitor
No references found
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) ↗
Serine/threonine-protein kinase mTORINHIBITOR
MTOR inhibitor
No references found
- Serine/threonine-protein kinase mTOR (MTOR) ↗

Chemistry & pharmacology

Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL3545323 ↗

Also known as

pwt-33579
pwt33597

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01407380	Phase 1	Jun 1, 2011	Pathway Therapeutics, Inc.

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Pathway Therapeutics, Inc.	For profit	1	1	1	2011

1 organizations

Page 1 / 1